II期临床研究-话题@MedSci

#II期临床研究#

109篇内容 | 2970人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1650007, encodeId=0ce3165000e60, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=Lancet Infect Dis：II价艰难梭菌疫苗III期临床研究失败, objectType=article, longId=200768, objectId=614b200e686d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=614b200e686d, replyNumber=0, likeNumber=71, createdTime=2021-02-10, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=614b200e686d, moduleTitle=Lancet Infect Dis：II价艰难梭菌疫苗III期临床研究失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=614b200e686d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650009, encodeId=e269165000996, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=君实生物特瑞普利单抗一线治疗鼻咽癌III期临床研究PFS预估显著, objectType=article, longId=201382, objectId=2172201382b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2172201382b6, replyNumber=0, likeNumber=71, createdTime=2021-04-17, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2172201382b6, moduleTitle=君实生物特瑞普利单抗一线治疗鼻咽癌III期临床研究PFS预估显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2172201382b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650019, encodeId=5ede1650019ba, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=Medsenic宣布Arscimed®治疗慢性移植物抗宿主病(cGvHD)的II期临床研究取得阳性结果, objectType=article, longId=209280, objectId=187220928040, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=187220928040, replyNumber=0, likeNumber=69, createdTime=2021-10-17, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=187220928040, moduleTitle=Medsenic宣布Arscimed®治疗慢性移植物抗宿主病(cGvHD)的II期临床研究取得阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=187220928040)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650028, encodeId=7cf316500284d, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=JCO: Ixazomi联合来那度胺+地塞米松治疗复发或难治性多发性骨髓瘤（RRMM）的最终分析结果：III期临床研究TOURMALINE-MM1, objectType=article, longId=212671, objectId=87bb2126e1d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87bb2126e1d5, replyNumber=0, likeNumber=52, createdTime=2021-07-01, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87bb2126e1d5, moduleTitle=JCO: Ixazomi联合来那度胺+地塞米松治疗复发或难治性多发性骨髓瘤（RRMM）的最终分析结果：III期临床研究TOURMALINE-MM1, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=87bb2126e1d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650025, encodeId=ebbd165002541, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=百时美施贵宝公布III期临床研究CheckMate -9LA两年随访数据，结果喜人！, objectType=article, longId=210359, objectId=837e210359f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=837e210359f2, replyNumber=0, likeNumber=75, createdTime=2021-10-10, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=837e210359f2, moduleTitle=百时美施贵宝公布III期临床研究CheckMate -9LA两年随访数据，结果喜人！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=837e210359f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650006, encodeId=4cc31650006ed, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=食管癌及胃食管连接部癌术后欧狄沃（纳武利尤单抗）辅助治疗III期临床研究CheckMate -577达到主要终点无病生存期, objectType=article, longId=199310, objectId=a5e8199310d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5e8199310d0, replyNumber=0, likeNumber=55, createdTime=2020-12-19, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5e8199310d0, moduleTitle=食管癌及胃食管连接部癌术后欧狄沃（纳武利尤单抗）辅助治疗III期临床研究CheckMate -577达到主要终点无病生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5e8199310d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650020, encodeId=3928165002001, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=NEJM：Nivolumab辅助治疗方案用于晚期食管或胃食管交界癌患者III期临床研究获得成功, objectType=article, longId=209558, objectId=b719209558c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b719209558c2, replyNumber=0, likeNumber=0, createdTime=2021-06-27, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b719209558c2, moduleTitle=NEJM：Nivolumab辅助治疗方案用于晚期食管或胃食管交界癌患者III期临床研究获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b719209558c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650021, encodeId=4e25165002170, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=III期临床研究CheckMate -816结果发布：欧狄沃®（纳武利尤单抗）联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善肿瘤病理完全缓解, objectType=article, longId=209763, objectId=515e209e63ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=515e209e63ce, replyNumber=0, likeNumber=31, createdTime=2021-09-02, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=515e209e63ce, moduleTitle=III期临床研究CheckMate -816结果发布：欧狄沃®（纳武利尤单抗）联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善肿瘤病理完全缓解, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=515e209e63ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650002, encodeId=59031650002db, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=Moderna的新冠病毒候选疫苗mRNA-1273，获得FDA批准进行II期临床研究, objectType=article, longId=193802, objectId=898d1938022e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=898d1938022e, replyNumber=0, likeNumber=53, createdTime=2020-07-07, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=898d1938022e, moduleTitle=Moderna的新冠病毒候选疫苗mRNA-1273，获得FDA批准进行II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=898d1938022e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650018, encodeId=a00a1650018d2, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=脱发新疗法！FOL-005的II期临床研究已接近尾声, objectType=article, longId=206428, objectId=acf720642822, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=acf720642822, replyNumber=0, likeNumber=74, createdTime=2021-02-20, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=acf720642822, moduleTitle=脱发新疗法！FOL-005的II期临床研究已接近尾声, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=acf720642822)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650014, encodeId=6c9c1650014d6, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=患者招募：重组人源化抗PD-1单克隆抗体（HX008）联合化疗对比帕博利珠单抗联合化疗作为一线方案治疗晚期或转移性非鳞非小细胞肺癌（NSCLC）的II/III期临床研究, objectType=article, longId=204948, objectId=3cf1204948c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3cf1204948c8, replyNumber=0, likeNumber=84, createdTime=2021-06-02, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3cf1204948c8, moduleTitle=患者招募：重组人源化抗PD-1单克隆抗体（HX008）联合化疗对比帕博利珠单抗联合化疗作为一线方案治疗晚期或转移性非鳞非小细胞肺癌（NSCLC）的II/III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3cf1204948c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650011, encodeId=4df1165001143, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=信达生物公布信迪利单抗联合贝伐珠单抗一线治疗肝癌III期临床研究结果, objectType=article, longId=203674, objectId=94d42036e4b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94d42036e4b2, replyNumber=0, likeNumber=63, createdTime=2020-11-28, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94d42036e4b2, moduleTitle=信达生物公布信迪利单抗联合贝伐珠单抗一线治疗肝癌III期临床研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94d42036e4b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650008, encodeId=9c761650008ac, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=ADAURA III期临床研究结果公布：奥希替尼治疗中枢神经系统转移可改善无病生存期, objectType=article, longId=201090, objectId=24af2010905f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24af2010905f, replyNumber=0, likeNumber=52, createdTime=2021-05-08, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24af2010905f, moduleTitle=ADAURA III期临床研究结果公布：奥希替尼治疗中枢神经系统转移可改善无病生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24af2010905f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650013, encodeId=a7ba165001326, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=患者招募：吡咯替尼联合沙利度胺治疗HER2突变型非小细胞肺癌的单臂、开放、前瞻性II期临床研究, objectType=article, longId=204833, objectId=e12e20483351, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e12e20483351, replyNumber=0, likeNumber=81, createdTime=2021-07-04, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e12e20483351, moduleTitle=患者招募：吡咯替尼联合沙利度胺治疗HER2突变型非小细胞肺癌的单臂、开放、前瞻性II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e12e20483351)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650003, encodeId=d2ed165000330, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=ASCO 2020：MEK162（贝美替尼）联合伊马替尼治疗晚期胃肠道间质瘤II期临床研究, objectType=article, longId=194645, objectId=1e85194645d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e85194645d2, replyNumber=0, likeNumber=67, createdTime=2020-06-16, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e85194645d2, moduleTitle=ASCO 2020：MEK162（贝美替尼）联合伊马替尼治疗晚期胃肠道间质瘤II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e85194645d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650001, encodeId=c41b165000173, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=ONC201治疗胶质瘤的I / II期临床研究即将在日本开展, objectType=article, longId=191301, objectId=64bf1913012b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64bf1913012b, replyNumber=0, likeNumber=67, createdTime=2020-08-03, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64bf1913012b, moduleTitle=ONC201治疗胶质瘤的I / II期临床研究即将在日本开展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=64bf1913012b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650004, encodeId=88521650004b7, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=靶向Aβ的阿尔茨海默症新药BAN2401，开始III期临床研究, objectType=article, longId=197608, objectId=a82f19e608e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a82f19e608e8, replyNumber=0, likeNumber=56, createdTime=2021-04-17, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a82f19e608e8, moduleTitle=靶向Aβ的阿尔茨海默症新药BAN2401，开始III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a82f19e608e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650005, encodeId=73ba16500059d, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=COVID-19疫苗BNT162b2进入II / III期临床研究, objectType=article, longId=198193, objectId=ccfa198193ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccfa198193ff, replyNumber=0, likeNumber=60, createdTime=2020-11-05, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccfa198193ff, moduleTitle=COVID-19疫苗BNT162b2进入II / III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ccfa198193ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649997, encodeId=0308164999e08, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=维昇药业宣布其TransCon人生长激素，在中国未经修饰的长效人生长激素即将在国内开展III期临床研究, objectType=article, longId=182069, objectId=fe64182069a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe64182069a8, replyNumber=0, likeNumber=74, createdTime=2020-07-17, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe64182069a8, moduleTitle=维昇药业宣布其TransCon人生长激素，在中国未经修饰的长效人生长激素即将在国内开展III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe64182069a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649996, encodeId=3b8c1649996dd, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=III期临床研究CheckMate -9LA达到主要研究终点，与单独化疗相比，欧狄沃®（纳武利尤单抗）与低剂量伊匹木单抗联合化疗用于肺癌一线治疗，患者总生存获益, objectType=article, longId=181894, objectId=a3881818949e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3881818949e, replyNumber=0, likeNumber=118, createdTime=2020-08-28, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3881818949e, moduleTitle=III期临床研究CheckMate -9LA达到主要研究终点，与单独化疗相比，欧狄沃®（纳武利尤单抗）与低剂量伊匹木单抗联合化疗用于肺癌一线治疗，患者总生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3881818949e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

II期临床研究

2020-05-29

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

Lancet Infect Dis：II价艰难梭菌疫苗III期临床研究失败

2021-02-10

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

君实生物特瑞普利单抗一线治疗鼻咽癌III期临床研究PFS预估显著

2021-04-17

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

Medsenic宣布Arscimed®治疗慢性移植物抗宿主病(cGvHD)的II期临床研究取得阳性结果

2021-10-17

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

JCO: Ixazomi联合来那度胺+地塞米松治疗复发或难治性多发性骨髓瘤（RRMM）的最终分析结果：III期临床研究TOURMALINE-MM1

2021-07-01

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

百时美施贵宝公布III期临床研究CheckMate -9LA两年随访数据，结果喜人！

2021-10-10

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

食管癌及胃食管连接部癌术后欧狄沃（纳武利尤单抗）辅助治疗III期临床研究CheckMate -577达到主要终点无病生存期

2020-12-19

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

NEJM：Nivolumab辅助治疗方案用于晚期食管或胃食管交界癌患者III期临床研究获得成功

2021-06-27

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

III期临床研究CheckMate -816结果发布：欧狄沃®（纳武利尤单抗）联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善肿瘤病理完全缓解

2021-09-02

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

Moderna的新冠病毒候选疫苗mRNA-1273，获得FDA批准进行II期临床研究

2020-07-07

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

脱发新疗法！FOL-005的II期临床研究已接近尾声

2021-02-20

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

患者招募：重组人源化抗PD-1单克隆抗体（HX008）联合化疗对比帕博利珠单抗联合化疗作为一线方案治疗晚期或转移性非鳞非小细胞肺癌（NSCLC）的II/III期临床研究

2021-06-02

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

信达生物公布信迪利单抗联合贝伐珠单抗一线治疗肝癌III期临床研究结果

2020-11-28

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

ADAURA III期临床研究结果公布：奥希替尼治疗中枢神经系统转移可改善无病生存期

2021-05-08

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

患者招募：吡咯替尼联合沙利度胺治疗HER2突变型非小细胞肺癌的单臂、开放、前瞻性II期临床研究

2021-07-04

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

ASCO 2020：MEK162（贝美替尼）联合伊马替尼治疗晚期胃肠道间质瘤II期临床研究

2020-06-16

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

ONC201治疗胶质瘤的I / II期临床研究即将在日本开展

2020-08-03

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

靶向Aβ的阿尔茨海默症新药BAN2401，开始III期临床研究

2021-04-17

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

COVID-19疫苗BNT162b2进入II / III期临床研究

2020-11-05

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

维昇药业宣布其TransCon人生长激素，在中国未经修饰的长效人生长激素即将在国内开展III期临床研究

2020-07-17

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

III期临床研究CheckMate -9LA达到主要研究终点，与单独化疗相比，欧狄沃®（纳武利尤单抗）与低剂量伊匹木单抗联合化疗用于肺癌一线治疗，患者总生存获益

2020-08-28

科室
- - 订阅+
  - 更多科室
工具
服务